Deals In Depth: April 2017
Executive Summary
Janssen got development and commercialization rights to PeptiDream's macrocyclic/constrained peptides in cardio-metabolic diseases; BD added to its strong position in medication management and infection prevention through the $23 billion takeover of Bard. A nearly $2 billion IPO by Galenica Sante helped boost biopharma financing.